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A B S T R A C T
The majority of mutations identified in patients with amelogenesis imperfecta have been mapped to FAM83H. As
FAM83H expression is not limited to the enamel, how FAM83H contributes to amelogenesis is still largely
unknown. We previously reported that members of the FAM83 family of proteins interact with and regulate the
subcellular distribution of the promiscuous serine-threonine protein kinase CK1 family, through their shared N-
terminal DUF1669 domains. FAM83H co-localises with CK1 isoforms to speckle-like structures in both the cy-
toplasm and nucleus. In this report, we show FAM83H, unlike other FAM83 proteins, interacts and colocalises
with NCK1/2 tyrosine kinase adaptor proteins. This interaction is mediated by proline-rich motifs within the C-
terminus of FAM83H, specifically interacting with the second and third SH3 domains of NCK1/2. Moreover,
FAM83H pathogenic AI mutant proteins, which trigger C-terminal truncations of FAM83H, retain their inter-
actions with CK1 isoforms but lose interaction with NCK1/2. These AI mutant FAM83H proteins acquire a
nuclear localisation, and recruit CK1 isoforms to the nucleus where CK1 retains its kinase activity. As under-
standing the constituents of the FAM83H-localised speckles may hold the key to unravelling potential substrates
of FAM83H-associated CK1 substrates, we employed a TurboID-based proximity labelling approach and un-
covered several proteins including Iporin and BAG3 as potential constituents of the speckles.
1. Introduction
FAM83H is a member of the FAMily with sequence similarity 83
(FAM83) protein family, which comprises eight family members de-
signated FAM83A-H. FAM83 proteins are related by a common N-
terminal domain of unknown function called DUF1669. The function of
this protein family is mostly uncharacterised, however we have recently
identified that FAM83 proteins act as scaffolding proteins for protein
kinase CK1 isoforms α, δ and ε, where FAM83 proteins serve to direct
CK1 isoforms to distinct subcellular compartments. The FAM83:CK1
interaction is mediated through the DUF1669 domain, which we re-
named Protein Anchor of CK1 (PACK1) [1,2].
Outside of the PACK1 domain, the FAM83 proteins are unique and
share no sequence similarity or homology. Consistent with this, we
have found that different FAM83 members have unique interacting
partners and cellular roles [2–6]. By employing a proteomics approach,
we identified FAM83G, also known as Protein Associated with SMAD1
(PAWS1), as a novel interactor of SMAD1 and a novel component of the
BMP signaling pathway [3]. Moreover, through its association with
CK1α, PAWS1 can activate the Wnt signaling pathway [5] and muta-
tions in PAWS1 that are implicated in palmoplantar keratoderma, lose
interaction with CK1α and consequently have attenuated Wnt signaling
[7]. Interestingly, we found that the interaction between FAM83D and
CK1α was essential for proper positioning of mitotic spindles, and in the
process uncovered CK1α as a novel mitotic kinase with important
functions in cell division [6].
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FAM83H has also been reported to be overexpressed in several types
of cancers, including colorectal cancer [8,9], hepatocellular carcinoma
[10] and prostate cancer [11]. Nevertheless, FAM83H is the only
FAM83 member implicated in amelogenesis, as mutations in FAM83H
have been identified in patients with autosomal dominant hypocalcified
amelogenesis imperfecta (ADHCAI) [12–31]. Amelogenesis imperfecta
(AI) refers to genetic conditions in which enamel formation is com-
promised. This affects the appearance and structure of the enamel of
primary and secondary dentition and consequently has detrimental
effects on the psychosocial health of those impacted. The hypocalcified
phenotype is thought to be the most severe form of AI in which enamel
has normal thickness, but is soft, discoloured and wears away shortly
after eruption. Prior to 2008, causative genetic mutations for ADHCAI
had not been identified in genes that had previously been implicated in
AI or known to be involved in amelogenesis. Thus, novel candidate
genes whose mutations could explain the pathogenesis of AI were
sought after. The putative disease locus was narrowed down to a 2.1 Mb
region composed of 91 genes on chromosome 8q 24.3 between
FAM135B and the telomere [32]. Through sequencing 42 genes in that
2.1 Mb region, two nonsense mutations were mapped to the terminal
exon of FAM83H, Exon 5 [12]. At present, over 20 mutations in
FAM83H, all mapped to Exon 5, have been reported (Fig. 1). With the
exception of two missense mutations [16,17], all other mutations are
predicted to encode a premature stop codon and consequently encode a
truncated FAM83H protein. All mutations affect the protein outside the
DUF1669/PACK1 domain between and including residues S287 and
E694 [26].
FAM83H is not solely expressed during amelogenesis and is thought
to be expressed ubiquitously [12,23]. It has not previously been im-
plicated in amelogenesis and therefore the significance of FAM83H
mutations in amelogenesis imperfecta and why there is an absence of
non-dental phenotypes in patients with these mutations remains a
mystery. As the C-terminus of FAM83H is lost in these FAM83H trun-
cation mutants, it is predicted that the C-terminus of FAM83H is im-
portant for the correct calcification of enamel [13], however the exact
roles of FAM83H in amelogenesis are unknown. FAM83H is not ex-
pected to be secreted into the enamel matrix as it lacks a secretory
signal peptide and is therefore expected to have intracellular roles in
ameloblasts. However, whether FAM83H mainly functions during the
pre-secretory, secretory or maturation stage of amelogenesis remains
unclear [23,33].
In this study, we sought to characterise the role of the FAM83H
protein and how the AI mutants modulate FAM83H function. We have
employed a combination of proteomic, biochemical and cellular ap-
proaches to dissect the interactors and subcellular distribution of
FAM83H, and the AI mutants and assess their impact on CK1 kinase
activity.
2. Materials and methods
2.1. Plasmids
Recombinant DNA procedures were performed using standard pro-
tocols as described previously [34]. Constructs for transient transfection
were subcloned into pcDNA5-FRT/TO vectors and constructs for ret-
roviral transfection were subcloned into a pBABE vector with either
EGFP, FLAG or an mCherry tag at the N or C-terminus as indicated. All
constructs are available to request from the Medical Research Council
(MRC) – Phosphorylation and Ubiquitylation Unit (PPU) Reagents
webpage (http://mrcppureagents.dundee.ac.uk) and the unique iden-
tifier (DU) numbers indicated below provide direct links to the cloning
strategy and sequence information. The following constructs were
generated:
pcDNA5-FRT/TO GFP (DU 41455), pcDNA5-FRT/TO FLAG empty
(DU 41457), pCMV GAG/POL (Clontech), pCMV VSV-G (Clontech)
pcDNA5-FRT/TO CK1α-mCherry (DU 28469), pcDNA5-FRT/TO
mCherry-CK1α (DU 28407), pcDNA5-FRT/TO GFP-FAM83H (DU
44239), pcDNA5-FRT/TO GFP-FAM83HD236A (DU 28428), pcDNA5-
FRT/TO GFP-FAM83HF270A (DU 28487), pcDNA5-FRT/TO FLAG-
FAM83HM1-E50 (DU 29071), pcDNA5-FRT/TO FLAG-FAM83HP301-F350
(DU 29070), pcDNA5-FRT/TO FLAG-FAM83HI898-A948 (DU 29068),
pcDNA5-FRT/TO FLAG-FAM83HA948-P999 (DU 29069), pcDNA5-FRT/TO
FLAG-FAM83H (DU 28811), pcDNA5-FRT/TO FLAG-FAM83HD236A (DU
28893), pcDNA5-FRT/TO FLAG-FAM83HF247A (DU 28890), pcDNA5-
FRT/TO FLAG-FAM83HF251A (DU 28892), pcDNA5-FRT/TO FLAG-
FAM83HF270A (DU 28827), pcDNA5-FRT/TO FLAG-FAM83HF274A (DU
28822), pcDNA5-FRT/TO FLAG-FAM83HF278A (DU 28820), pcDNA5-
FRT/TO FLAG-FAM83HF350A (DU 28889), pcDNA5-FRT/TO FLAG-
FAM83HF354A (DU 28821), pcDNA5-FRT/TO FLAG-FAM83HA31E (DU
29553), pcDNA5-FRT/TO FLAG-FAM83HS287X (DU 28824), pcDNA5-
FRT/TO FLAG-FAM83HS287X, D236A (DU 64222), pcDNA5-FRT/TO FLAG-
FAM83HQ452X (DU 28826), pcDNA5-FRT/TO FLAG-FAM83HE694X (DU
28825), pcDNA5-FRT/TO FLAG-FAM83HS342T (DU 29598), pcDNA5-
FRT/TO FLAG-FAM83HG557C (DU 29599), pcDNA5-FRT/TO mCherry-
NCK1 (DU 28583), pcDNA5-FRT/TO NCK1-mCherry (DU 28689),
pcDNA5-FRT/TO mCherry-NCK2 (DU 28691), pcDNA5-FRT/TO FLAG-
NCK1 (DU 28906), pcDNA5-FRT/TO FLAG-NCK1R308M (DU 28921),
pcDNA5-FRT/TO FLAG-NCK1W39K (DU 28922), pcDNA5-FRT/TO FLAG-
NCK1W39K, W143K (DU 28927), pcDNA5-FRT/TO FLAG-NCK1W39K, W143K,
W229K (DU 28947), pcDNA5-FRT/TO FLAG-NCK1W39K, W229K (DU
28929), pcDNA5-FRT/TO FLAG-NCK1W143K (DU 28923), pcDNA5-FRT/
TO FLAG-NCK1W144K, W229K (DU 28954), pcDNA5-FRT/TO FLAG-
NCK1W229K (DU 28925), pcDNA5-FRT/TO FLAG-NCK2 (DU 28907),
pcDNA5-FRT/TO FLAG-NCK2R311M (DU 28935), pcDNA5-FRT/TO
FLAG-NCK2W39K (DU 28936), pcDNA5-FRT/TO FLAG-NCK2W39K, W149K
1 2 3 4 5
247 - 1179
205 - 246 






Fig. 1. FAM83H AI mutations.
Schematic diagram representing the genomic loca-
tion of the mutations identified in the FAM83H gene
implicated in amelogenesis imperfecta. Exons are
represented by boxes, where coding regions are
shaded in blue, and non-coding regions shaded in
grey. Numbers correspond to the number of the
nucleotide base pair. Introns are represented by
straight blue lines. The length of vertical lines in-
dicates the number of families reported with the
mutation.
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(DU 28939), pcDNA5-FRT/TO FLAG-NCK2W39K, W149K, W235K (DU
28948), pcDNA5-FRT/TO FLAG-NCK2W39K, W235K (DU 28955), pcDNA5-
FRT/TO FLAG-NCK2W149K (DU 28937), pcDNA5-FRT/TO FLAG-
NCK2W39K, W149K (DU 28940), pcDNA5-FRT/TO FLAG-NCK2W235K (DU
28938), pBABED puro FLAG-aGFP6M (DU 57701), pBABED puro FLAG-
TurboID (DU 29701), pBABED puro FLAG-TurboID-aGFP6M (DU 29702).
pBABED puro (DU 33932). Constructs used in CRISPR/Cas9 gene editing
pBABED-Puro-sgRNA1 FAM83H KO sense guide RNA (gRNA; DU52010)
and pX335-Cas9-D10A-sgRNA2 FAM83H KO antisense gRNA (DU52026)
for knockout of FAM83H; pBABED-Puro-sgRNA1 FAM83H C-terminal KI
sense gRNA (DU 54452), pX335-Cas9-D10A-sgRNA2 FAM83H C-term-
inal KI antisense gRNA (DU54457), pMK-RQ FAM83H GFP donor (DU
54697) for endogenous C-terminal knockin of GFP. pBABED-Puro-
sgRNA1 CSNK1A1 N-terminal KI sense gRNA (DU 57522), pX335-Cas9-
D10A-sgRNA2 CSNK1A1 N-terminal KI antisense gRNA (DU 57527),
pMK-RQ CSNK1A1 mCherry donor (DU 57578) for endogenous N-
terminal knockin of mCherry to CSNK1A1. pBABED-Puro-sgRNA1
CSNK1D N-terminal KI sense gRNA (DU 57523), pX335-Cas9-D10A-
sgRNA2 CSNK1D N-terminal KI antisense gRNA (DU 57528), pMK-RQ
CSNK1D mCherry donor (DU 57702) for endogenous N-terminal knockin
of mCherry to CSNK1D. pBABED-Puro-sgRNA1 CSNK1E N-terminal KI
sense gRNA (DU 54377), pX335-Cas9-D10A-sgRNA2 CSNK1D N-term-
inal KI antisense gRNA (DU 54383), pMK-RQ CSNK1E mCherry donor
(DU 57623) for endogenous N-terminal knockin of mCherry to CSNK1E.
Sequences of constructs were verified by the DNA Sequencing Service,
University of Dundee (www.dnaseq.co.uk).
2.2. Antibodies
Primary antibodies used in Western blotting were diluted in either
5% milk/TBS-T (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (v/v)
Tween 20) or 5% BSA/TBS-T and are as follows: anti-alpha-tubulin
(MA1–80189, Thermo Scientific, rat monoclonal, 1:2000, BSA), anti-
CK1α (A301-991A, Bethyl, rabbit polyclonal 1:1000, milk), anti-CK1α
(SA527, MRC-PPU Reagents, sheep polyclonal, 1:1000, milk) anti-CK1δ
(SA609, MRC-PPU Reagents, sheep polyclonal, 1:1000, milk), anti-CK1ε
(HPA026288, Sigma, rabbit polyclonal, 1:1000, milk), anti-CK1ε
(SA610, MRC-PPU Reagents, sheep polyclonal, 1:1000, milk) anti-
FAM83H (SA273, MRC-PPU Reagents, sheep polyclonal, 1:1000, milk),
anti-FLAG M2-Peroxidase (A8592, Sigma, mouse monoclonal, 1:2000,
milk) anti-GAPDH (2118, Cell Signaling Technology, rabbit mono-
clonal, 1:2000, BSA), anti-GFP (S268B, MRC-PPU Reagents, sheep
polyclonal, 1:2000, milk), anti-mCherry (ab183628 Abcam, rabbit
polyclonal, 1:1000, milk), anti-NCK1 (2319, Cell Signaling Technology,
rabbit monoclonal, 1:500, milk) and Streptavidin-HRP (89880D, Pierce,
1:2000, 5% BSA/TBS).
Secondary antibodies used in Western blotting were diluted in 5%
milk/TBS-T and are as follows: horse anti-mouse IgG HRP (7076, Cell
Signaling Technology, 1:5000), goat anti-rabbit IgG HRP (7074, Cell
Signaling Technology 1:5000), rabbit anti-sheep IgG HRP (31480,
Thermo Fisher Scientific, 1:5000), goat anti-rat IgG (H+L) IRDye® 800
CW (P/N 925-68029, Licor, 1:10000), StarBright Blue 700 goat anti-
rabbit IgG (12004161, Bio-Rad, 1:10000).
Antibodies used in immunofluorescence were diluted in 3% BSA/
PBS and are as follows: anti-FLAG (14,793, Cell Signaling Technology,
rabbit monoclonal, 1:400), Alexa Fluor 488 donkey anti rabbit IgG
(H + L) (A21206, Cell Signaling Technology, 1:300), Alexa Fluor 488
donkey anti sheep IgG (H + L) (A11015, Cell Signaling Technology,
1:300), Alexa Fluor 488 goat anti rabbit IgG (H + L) (A11034, Cell
Signaling Technology, 1:300), Alexa Fluor 594 donkey anti goat IgG
(H + L) (A11058, Cell Signaling Technology, 1:300), Alexa Fluor 594
donkey anti-sheep IgG (H + L) (A11016, Cell Signaling Technology,
1:300), Streptavidin, Alexa Fluor 594 conjugate (S32356, Life
Technologies, 1:300).
2.3. Cell culture
U2OS osteosarcoma (HTB-96, ATCC), HEK-293 human embryonic
kidney (CRL-1573, ATCC) and A549 human pulmonary adenocarci-
noma (CCL-185, ATCC) cells were grown in Dulbecco's modified Eagle's
medium (DMEM: 11960–085, GIBCO) supplemented with 10% (v/v)
foetal bovine serum (FBS) (F7524, Sigma), 2 mM L-glutamine
(25030024, GIBCO), 100 U/mL penicillin-streptomycin (15140122,
GIBCO). Cells were incubated at 37 °C, 5% CO2 in a humidified atmo-
sphere.
For transient transfections, 20 μl of polyethylenimine (PEI, 1 mg/
ml) (24765, Polysciences Inc) and 2 μg of plasmid DNA was added to
1 mL of Opti-Mem (31985–062, GIBCO). This mixture was then gently
vortexed for 20 s then incubated at room temperature for 20 min. After
incubation, the transfection mixture was added drop by drop to the
media of cells in a 10 cm dish.
To induce the expression of FAM83-GFP or GFP-FAM83 proteins in
U2OS or HEK-293 Flp-In T-Rex cells respectively, cells were incubated
in 20 ng/mL doxycycline for 24 h.
2.4. Generation of stable Flp-In T-Rex cell lines
U2OS or HEK-293 cell lines stably expressing FAM83 proteins with
a C or N-terminal GFP tag, respectively, were generated as described
previously [1].
2.5. Generation of U2OS FAM83H−/− using CRISPR/Cas9
Generation of U2OS FAM83H−/− has been previously described
[1]. To summarise, CRISPR/Cas9 gene editing technology was used to
knockout FAM83H in U2OS cells. U2OS cells at 60% confluency grown
in a 10 cm dish were transfected with 1 μg of two separate plasmid
vectors encoding antisense and sense guide RNAs (pBABED-Puro-
sgRNA1 FAM83H KO sense guide RNA (gRNA; DU52010) and pX335-
Cas9-D10A-sgRNA2 FAM83H KO antisense gRNA (DU52026)) that
target the first coding exon of FAM83H, Exon 2. After 16 h, the media of
the cells were changed and cells were selected in 2 μg/mL puromycin
(P9620, Sigma) for two days. The transfection was repeated and 16 h
after this transfection the cell media was replaced with fresh media.
Cells were isolated by single cell sorting and were plated into separate
wells of two 96-well plates precoated with 1% (w/v) gelatine (G7765,
Sigma). Cell clones that survived and proliferated were expanded and
knockout was confirmed by Western blotting and DNA sequencing of
the genomic region targeted by CRISPR/Cas9.
2.6. Generation of A549 FAM83HGFP/GFP and U2OS CK1mCherry/mCherry
using CRISPR/Cas9
A549 cells were transfected with 1 μg of each plasmid vector en-
coding antisense and sense guide RNAs for FAM83H (pBABED-Puro-
sgRNA1 FAM83H C-terminal KI sense (DU 54452), pX335-Cas9-D10A-
sgRNA2 FAM83H C-terminal KI antisense (DU54457)), which target the
region proximal to the stop codon of FAM83H, and 3 μg of a donor
plasmid (pMK-RQ FAM83H GFP donor (DU 54697)), which contains the
gene encoding enhanced GFP (EGFP) flanked by 5′ and 3′ homology
arms. 16 h after transfection, cells were selected in 2 μg/mL puromycin
(Sigma, P9620) for 48 h. The transfection was repeated. 16 h after this
transfection, the cell media was replaced with fresh media.
Fluorescence activated cell sorting was employed to isolate GFP-posi-
tive cells. Single GFP-positive cell clones were plated into single wells of
two 96-well plates precoated with 1% (w/v) gelatine (G7765, Sigma).
Surviving cell clones were expanded and endogenous knockin of GFP to
the C-terminus of FAM83H was verified by Western blotting and
genomic sequencing of the targeted locus.
For knockin in the mCherry tag to endogenous CK1 isoforms, the
same protocol was performed using U2OS cells except with the
T. Tachie-Menson, et al. Cellular Signalling 72 (2020) 109632
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following constructs: pBABED-Puro-sgRNA1 CSNK1 N-terminal KI sense
gRNAs (DU 57522, DU 57523 or DU 54377), pX335-Cas9-D10A-
sgRNA2 CSNK1 N-terminal KI antisense gRNA (DU 57527, DU 57528 or
DU 54383), which target the 3′ end of the 5′UTR and the start of exon 1
CSNK1A1, CSNK1D or CSNK1E, and 3 μg of a donor plasmid (pMK-RQ
CSNK1 mCherry donor (DU 57578, DU 57702 or DU 57623), which
contains the gene encoding mCherry and a 3′ 5× poly-glycine linker.
2.7. Generation of stable cell lines by retroviral transduction
6 μg of retroviral pBABE vectors, 3.2 μg pCMV5-GAG/POL, 2.8 μg
pCMV5-VSV-G and 24 μl PEI (1 mg/ml) were added to 1 mL of Opti-
Mem (31985–062, GIBCO). The mixture was vortexed gently then in-
cubated at room temperature for 20 min. The transfection mixture was
added drop by drop to HEK-293-FT cells at around 70% confluency
growing within a 10 cm diameter cell culture dish. 24 h after trans-
fection, the cell media was changed. 24 h later, the media containing
retroviruses was collected and passed through 0.22 μm sterile filters.
The target cell lines, at 60% confluency, were then retrovirally trans-
duced by incubating cells with viral media, at the appropriate viral
titre, in the presence of 8 μg/mL hexadimethrine bromide (also known
as polybrene, H9268, Sigma) for 24 h. The cell media was then replaced
with fresh media containing 2.5 μg/mL puromycin (P9620, Sigma) to
select cells that had been successfully transduced and had incorporated
the constructs. Cells were selected with puromycin for 48 h and then
incubated in fresh culture media.
2.8. Cell lysis
Generally, cells were washed twice in ice-cold PBS then scraped in
lysis buffer (50 mM Tris-HCl (pH 7.4), 270 mM sucrose, 150 mM NaCl,
1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0), 1 mM sodium orthova-
nadate, 10 mM sodium β-glycerophosphate, 50 mM sodium fluoride,
5 mM sodium pyrophosphate, and 1% (v/v) Nonidet P40 (492016,
Merck) supplemented with 1× EDTA-free protease inhibitor cocktail
(11873580001, Merck). Lysates were incubated on ice for 10 min, then
clarified by centrifugation at 17,000g for 10 min at 4 °C. The super-
natant (soluble cell extract) was collected in a fresh Eppendorf and
either snap frozen in liquid nitrogen and stored at −80 °C for later
processing or processed immediately after the protein concentration
was measured in a 96-well format using the Bradford protein assay
reagent (23236, Pierce).
TurboID experiments were adapted from the method described by
Branon et al. [35]. Briefly, Cells were incubated with biotin (B4501,
Sigma Aldrich) for 10 min at 37 °C then washed five times in ice cold
PBS. Cells were then scraped in PBS, pelleted by centrifugation at 300g
for 3 min at 4 °C, lysed in RIPA lysis buffer supplemented with 1×
EDTA-free protease inhibitor cocktail (11873580001, Merck), then
clarified as described above.
2.9. Immunoprecipitation
For immunoprecipitation, cell extracts (300–1000 μg of protein)
were incubated with 10 μL of GFP-trap A beads (gta-10, Chromotek) or
M2 anti-FLAG agarose gel (A2220, Sigma) for 1 h at 4 °C with rotation.
Beads were washed three times in lysis buffer or once in lysis buffer
supplemented to 250 mM NaCl, then twice in lysis buffer for samples
containing two or more epitope tags. Proteins were then eluted from
beads by boiling beads in 1× Laemmli sample buffer containing 5% (v/
v) 2-mercaptoethanol (5× Laemmli sample buffer was made as follows:
1 M Tris-HCl pH 6.8, 10% (w/v) SDS, 20% (v/v) glycerol, 0.5% (w/v)
bromophenol blue, 25% (v/v) 2-mercaptoethanol, ultrapure H2O) at
95 °C for 5 min.
For the affinity purification pertaining to the TurboID mass spec-
trometry experiments, cleared cell extracts (4 mg protein) were in-
cubated with 70 μL of streptavidin beads (17-5113-01, GE healthcare)
for 16 h with rotation at 4 °C. The beads were washed twice in RIPA
lysis buffer, once with 1 M KCl, once with 0.1 M Na2CO3, once with 2 M
urea in 10 mM Tris-HCl pH 8.0 then twice with RIPA lysis buffer.
Proteins were eluted in 70 μL 1× LDS sample buffer (NP0007,
Invitrogen) containing 5 mM DTT supplemented with an additional
20 mM DTT and 2 mM biotin for 10 min at 95 °C.
2.10. SDS-PAGE and Western blotting
Reduced cell extracts (10 μg to 20 μg protein) or im-
munoprecipitates were resolved on 10% SDS-PAGE gels or 4–12%
NuPAGE bis-tris gradient gels (Invitrogen) by electrophoresis. Proteins
were transferred onto polyvinylidene fluoride (PVDF) membranes
(10344661, Millipore), that had been pre-activated in 100% (v/v)
methanol for 1 min. Membranes were blocked with 5% (w/v) non-fat
milk powder (Marvel) in TBS-T, then incubated with primary antibody
diluted in either 5% (w/v) milk in TBS-T or 5% (w/v) bovine serum
albumin (BSA) in TBS-T for either 1 h at room temperature or 24 h at
4 °C with shaking. Membranes were washed 3 times for 10 min in TBS-T
then incubated in secondary antibody for 1 h at room temperature
followed by washing in TBS-T 3 times for 10 min each. Proteins were
then detected by incubation with enhanced chemiluminescence reagent
(WBKLS0500, Millipore) and visualised using either a Chemidoc MP
system (17001402, Bio-Rad), medical-grade X-ray films (KAX1824,
ScotRad), Hyperfilm (28906837, GE Healthcare) or using the Odyssey
Imager (LI-COR).
2.11. Fluorescence microscopy
Cells were seeded onto sterile 16-mm diameter glass circle cover-
slips then transfected with 250 ng of the relevant plasmid DNA. 24 h
after transfection, cells were washed twice in PBS then fixed in 4% (w/
v) formaldehyde in PBS for 20 min at room temperature. Cells were
then washed twice in PBS then permeabilised with 0.2% (v/v) Nonidet
P-40 in PBS for 4 min. Cells were washed twice in PBS then blocked in
blocking solution (3% (w/v) BSA in PBS) for 30 min. Cells were in-
cubated in primary antibody diluted in blocking solution for 1 h at
room temperature. Cells were then washed 3 times in PBS for 5 min per
wash, then incubated in secondary antibody and 4′,6-diamidino-2-
phenylindole (DAPI, Sigma Aldrich, D9542, 1 μg/mL) diluted in
blocking solution for 1 h at room temperature. Cells were then washed
3 times in PBS for 5 min per wash, then washed in ultrapure water once.
Coverslips were dried cell side up, then mounted using VECTASHIELD
anti-fade mounting medium (H-1000, Vector Laboratories). Coverslips
were sealed with Covergrip coverslip sealant (89411-108, VWR) and
left to dry. Cells were visualised using a 60× lens (1- UB932, Olympus,
1.4 Lens NA) on DeltaVision Widefield Deconvolution Microscopy
(Applied Precision/GE Healthcare). Images were deconvolved using
softWoRx software (GE Healthcare) and processed using OMERO [36].
2.12. Mass spectrometry
U2OS or HEK-293 Flp-In T-Rex cells were induced to express GFP-
tagged FAM83 proteins, then lysates were processed for mass spectro-
metry as previously described [1]. For mass spectrometry analysis of
endogenous FAM83H protein-protein interactions, A549 FAM83HGFP/GFP
or A549 wild type cells were lysed and clarified as described above, then
passed through Costar Spin-X columns (8161, Corning). Soluble cell ex-
tracts (6 mg protein) were incubated with 12 μL of GFP-Trap A beads
(gta-10, Chromotek) for 16 h as described above. Proteins were eluted
and resolved using SDS-PAGE on a 4 to 12% NuPAGE bis-tris gradient gel
(Invitrogen). The gel was stained using InstantBlue (ISB1L, Expedeon),
then destained in ultrapure water. Gel pieces were excised, and proteins
digested with trypsin. Peptides were then analysed by mass spectrometry
using Liquid Chromatography-tandem Mass spectrometry (LC-MS/MS)
on a Linear ion trap-orbitrap hybrid mass spectrometer (Orbitrap-
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VelosPro, Thermo) coupled to a U3000 RSLC HPLC (Rapid Separation/
High Performance Liquid Chromatography; Thermo). See Fulcher et al.
[1] for a more detailed description of the protocol.
2.13. Protein expression and purification
GST-PAWS1-6xHis (DU 28293, MRC-PPU reagents) protein was
obtained from Dr. P. Bozatzi. The protein was first expressed in BL21
(DE3) Escherichia. coli as previously described [1], then affinity-purified
sequentially using reduced glutathione-Sepharose and nickel-agarose
columns.
2.14. Immunoprecipitation-in vitro kinase assay
After washing in lysis buffer three times, beads were washed once in
1 mL of 10 X kinase assay buffer (10× kinase assay buffer: 50 mM Tris-
HCl (pH 7.5), 0.1 mM EGTA, 10 mM magnesium acetate, 2 mM di-
thiothreitol (DTT)). 10 μL of beads was resuspended in 5 μL 10× kinase
assay buffer, 2 μg GST-PAWS1-6xHis (DU 28293, MRC-PPU reagents)
and made up to a total volume of 25 μL. Reactions were then incubated
with 0.1 mM [γ32P]-ATP (~500 cpm/pmol) for 30 min at 30 °C.
Reactions were quenched upon addition of 1× Laemmli sample buffer
containing 5% (v/v) 2-mercaptoethanol and boiling at 95 °C for 5 min.
Samples were resolved on a 4–12% NuPAGE bis-tris gradient gel
(Invitrogen) by SDS-PAGE. Gels were stained with InstantBlue (ISB1L,
Expedon), then destained in ultrapure water then dried. Radioactivity
was assessed by exposure of the gel to Hyperfilm (28906837, GE
Healthcare) overnight at −80 °C.
3. Results
3.1. FAM83H interacts with NCK1/2
We have previously employed a proteomic approach to identify the
interactors of each FAM83 member using HEK-293 and U2OS osteo-
sarcoma Flp-In T-REx cells stably expressing each FAM83 member with
an N- or C-terminal GFP tag respectively, under control of a tetracycline
inducible promoter [1]. Proteins associated with anti-GFP im-
munoprecipitates (IPs) for each FAM83 protein were identified by LC-
MS/MS (project PXD009335, PRIDE database (https://www.ebi.ac.uk/
pride/) [37]). We found that all FAM83 members interact with protein
kinase CK1 isoform α (CK1α), while FAM83A, B, E and H also inter-
acted with CK1 isoforms δ and ε (Fig. 2A) [1]. We have verified the
interaction between FAM83D and CK1α in mitosis and demonstrated
that it is necessary for correct spindle positioning in mitosis, and also
confirmed the interaction between FAM83D and DYNLL1 and HMMR
[6]. Similarly, we have validated the interactions of PAWS1 with CK1α
[5], CD2AP [4] and SMAD1 [3] (Fig. 2A). From the proteomics data,
the standout unique interactors identified for FAM83H were protein
UNC45 homolog A (UNC45A) and non-catalytic region of tyrosine ki-
nase adaptor proteins 1 and 2 (NCK1 and NCK2) (Fig. 2A). Indeed,
endogenous NCK1 was identified by immunoblotting in GFP-FAM83H
IPs of cell extracts from HEK-293 Flp-In T-REx cells induced to express
GFP-FAM83H under a tetracycline inducible promoter (Fig. 2B).
mCherry-UNC45A similarly co-precipitated with GFP-FAM83H when
transiently expressed in U2OS FAM8H-/- (generated using CRISPR/Cas9
technology [38]), but not with GFP control (Fig. 2C).
All but two AI mutations that are mapped to FAM83H lead to the
expression of truncated FAM83H proteins (Fig. 1). We investigated the
effects of these pathogenic mutations on the association with FAM83H
interactors. Firstly, we generated vectors encoding truncated FAM83H
proteins with an N-terminal FLAG tag that correspond to the three
mutations in FAM83H identified in some patients with ADHCAI,
namely FLAG-FAM83HS287X, FLAG-FAM83HQ452X and FLAG-
FAM83HE694X. S287X encodes the smallest truncated protein, Q452X is
one of the most frequently reported AI mutations, and E694X encodes
the largest truncated protein. These vectors were transiently transfected
into U2OS FAM83H-/- cells and extracts subjected to anti-FLAG IPs. All
three mutants retained interaction with CK1 isoforms, but lost inter-
action with NCK1 (Fig. 2D). Two missense mutations FAM83HS342T and
FAM83HG557C have also been reported in the literature, although the
accuracy in mapping these mutations has been questioned [39]. These
missense mutations, like wild type FAM83H, interacted with CK1 iso-
forms and NCK (Fig. 2E).
3.2. The interaction between FAM83H and CK1 is not mediated by the
canonical F-x-x-x-F motif
It was reported that an F-x-x-x-F motif mediates the binding of
PERIOD proteins to CK1 isoforms [40], where F represents phenylala-
nine and x is any amino acid. FAM83H residue F274 belongs to one
such conserved motif in FAM83H (F270-x-x-x-F274) and when mutated,
F274A abolishes CK1 binding [9]. However, we have found that the
binding between FAM83 proteins and CK1 was not solely dependent on
the F-x-x-x-F motif, as mutating the conserved Phe residue of other
FAM83 proteins equivalent to FAM83HF274 did not abolish CK1 binding
[1,5], suggesting that the interaction could be mediated through a
structural moiety rather than a canonical interaction motif. Human
FAM83H has four F-x-x-x-F motifs and three of these motifs are highly
conserved in vertebrates (Fig. 3A). We mutated all four FAM83H F-x-x-
x-F motifs, in which individual Phe residues from each motif were
mutated to alanine. Although we could not express FLAG-FAM83HF247A
successfully. Nevertheless, we found that only F270A and F274A mu-
tations attenuated the interaction with CK1 (Fig. 3B). Moreover, D236A
and A31E mutations, which do not conform to the F-x-x-x-F motif and
are conserved in other FAM83 proteins, also abolished the interaction
between FAM83H and CK1 isoforms, [1,7] (Fig. 3B).
3.3. The interaction between FAM83H and NCK is mediated by the second
and third SH3 domains of NCK
Next, we sought to map the determinants of the FAM83H-NCK in-
teraction. NCK1 and NCK2 comprise three N-terminal SH3 domains and
one C-terminal SH2 domain; so we generated dominant negative mutants
of NCK1 and NCK2 in which each domain of NCK was inactivated [41].
For NCK1, the single domain mutants were generated as follows: W39K,
W143K, W229K and R308M, which inactivated the first, second and
third SH3 domains (SH3-1*, SH3-2* and SH3-3*) and the SH2 domain
(SH2*) respectively (Fig. 4A). Double and triple SH3 domain mutants
were also generated (Fig. 4A). This was repeated for NCK2 (Fig. 4B). The
NCK1/2 domain mutants alongside wild-type NCK1/2 were tagged with
an N-terminal FLAG tag and transiently expressed in U2OS Flp-In T-REx
cells that had been induced to express FAM83H-GFP. For NCK1, wild
type, SH2* and SH3–1* robustly co-precipitated GFP-FAM83H but the
SH3–2* and SH3–3* single mutants, double or SH3–1/2/3 triple mutants
did not co-precipitate FAM83H-GFP (Fig. 4C). Similar results were ob-
served for NCK2 although only SH3–2/3 double mutants did not robustly
co-precipitate GFP-FAM83H (Fig. 4D).
The SH3 domains of NCK interact with proline rich motifs with a
minimum consensus sequence of P-x-x-P, where P represents proline
and x represents any amino acid [42,43]. Armed with the knowledge
that truncating FAM83H at residue E694 disrupts the interaction of
FAM83H with NCK1 (Fig. 2D), we hypothesised that NCK interacts with
proline rich motifs near the C-terminus of FAM83H. There are several
proline rich motifs after residue E694 of FAM83H. Therefore, 50 amino
acid fragments of FAM83H comprising these proline rich motifs were
generated (Fig. 4E). Two fragments were generated as negative con-
trols: FLAG-FAM83HM1–E50 which comprises one proline rich motif P14-
L15-A16-P17 and FLAG-FAM83HP301-P350, which had no proline rich
motifs. U2OS FAM83H-/- cells were transiently transfected with FLAG
empty vector and vectors encoding FLAG-FAM83HI898-A948, FLAG-
FAM83HA948-P999 and FLAG-FAM83HWT as well as FLAG-FAM83HM1-
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E50 and FLAG-FAM83HP301-P350 control vectors. NCK1 co-precipitated
with FLAG-FAM83HWT and, to a greater degree, FLAG-FAM83HI898-A948
but did not co-precipitate with FLAG-FAM83HM1–E50, FLAG-
FAM83HP301-P350, FLAG-FAM83HA948–P999 and FLAG empty vector
controls (Fig. 4F). Taken together, CK1 interacts with the N-terminus of
FAM83H via the DUF1669/PACK1 domain and NCK interacts with the
C-terminus of FAM83H (Fig. 4G).
3.4. Pathogenic AI FAM83H mutants co-localise with CK1 in the nucleus,
but do not colocalise with NCK
It has been previously reported that FAM83H forms cytoplasmic and
nuclear speckles when overexpressed and that CK1 colocalises with
FAM83H at these speckles [1,9,44]. Moreover, the interaction between
FAM83H and CK1 is necessary for speckle formation [1,9]. In U2OS
Fig. 2. FAM83H interacts with NCK adaptor proteins.
A Schematic diagram showing FAM83 proteins interact with CK1 isoforms and have unique interactors.
B HEK-293 Flp-In T-REx cells that express GFP-FAM83 proteins under a doxycycline inducible promoter were treated with 20 ng/mL doxycycline for 24 h and GFP
was pulled down from lysates then cell extracts (input) and pull downs (IP) were analysed by immunoblotting (IB). n = 3.
C U2OS FAM83H-/- cells were transiently transfected with vectors encoding GFP, GFP-FAM83H and/or mCherry-UNC45A and lysates subjected to anti-GFP pull
downs. Cell extracts (input) and pull downs (IP) were then analysed by Western blotting. n = 2.
D Empty FLAG vector (vector), FLAG-FAM83HS287X, FLAG-FAM83HQ452X, FLAG-FAM83HE694X and FLAG-FAM83HWT were transiently transfected into U2OS
FAM83H-/- cells. Untransfected U2OS FAM83H-/- cells (−) were used as an additional control. Anti-FLAG immunoprecipitations were performed on lysates and cell
extracts (input) and immunoprecipitates (IP) were analysed by Western blotting. n = 3.
E FLAG empty vector (vector), FLAG-FAM83HS342T, FLAG-FAM83HG557C, FLAG-FAM83HE694X and FLAG-FAM83HWT were transiently transfected into HEK-293 wild
type cells. Anti-FLAG pull downs were performed on lysates then cell extracts (input) and immunoprecipitates (IP) were analysed by Western blotting. n = 1.
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FAM83H-/- cells, transiently expressed mCherry-NCK1 and mCherry-
NCK2 colocalised with GFP-FAM83H primarily at cytoplasmic speckles,
but also exhibited some non-overlapping diffuse cytosolic localisation,
and did not colocalise with free, untethered GFP (Fig. 5A). Moreover,
when CK1α-mCherry or NCK1-mCherry was transiently expressed in
U2OS FAM83H-/- cells alongside FLAG-FAM83H wildtype or AI mutants
S287X, Q452X or E694X, CK1α-mCherry colocalised with wild type and
mutant FAM83H (Fig. 5B), whereas NCK1-mCherry only co-localised
with WT but not mutant FAM83H (Fig. 5C). The FAM83H mutants
exhibit a different localisation pattern to wild type FAM83H, as wild
type FAM83H was mostly observed to localise in cytoplasmic speckles,
whereas S287X and Q452X mutants mostly localise to the nucleus.
However, E694X mutant, which causes a less severe AI phenotype, has
both cytoplasmic and nuclear localisation (Fig. 5B, C). FAM83H AI
missense mutants FAM83HS342T and FAM83HG557C exhibited a similar
localisation pattern to wild type FAM83H where mCherry-CK1α
(Fig. 5D) and mCherry-NCK1 (Fig. 5E) colocalised with these mutants.
3.5. CK1 associated with FAM83HQ452X maintains kinase activity
Since CK1α was observed to colocalise with FAM83H disease mu-
tants, which have an altered subcellular localisation, one could infer
that these pathogenic mutants cause a mislocalisation of CK1α that may
cause CK1 to phosphorylate atypical substrates within the nucleus and
thereby lead to pathogenesis. Therefore, we sought to investigate
whether the kinase activity of CK1 was affected by its interaction with
FAM83H disease mutant Q452X. To do this, FLAG empty vector, FLAG-
FAM83HQ452X, FLAG-FAM83HD236A and FLAG-FAM83HWT were tran-
siently transfected into U2OS FAM83H-/- cells. Anti-FLAG IPs followed
by Western blotting confirmed the co-precipitation of CK1α and CK1ε
with Q452X and WT but not D236A nor FLAG empty vector (Fig. 6A).
Under these conditions, subjecting the anti-FLAG IPs to an in vitro ki-
nase assay with recombinant GST-PAWS1-His (a previously described
CK1 substrate [1]) and 32γ-ATP, revealed that PAWS1 phosphorylation
was observed with anti-FLAG IPs from both Q452X and WT extracts but
not from D236A nor FLAG alone extracts (Fig. 6B).
As the speckle localisation of FAM83H is dependent on interaction
with CK1 [1,9] and as CK1 maintained its kinase activity with the
Q452X mutant in vitro, we sought to investigate whether this nuclear
localisation of AI mutants is a result of the maintained interaction with
CK1, because no obvious canonical nuclear localisation signal could be
identified in any of these truncation mutants. The D236A point muta-
tion was introduced to the S287X mutant. To validate this mutant does
not interact with CK1, we performed co-IP experiments. FLAG empty
vector, FLAG-FAM83HD236A, FLAG-FAM83HS287X, FLAG-FAM83HS287X,
D236A and FLAG-FAM83HWT were transiently transfected into U2OS
FAM83H-/- cells. As expected, CK1α and CK1ε did not co-IP with FLAG
control, FLAG-FAM83HD236A nor FLAG-FAM83HS287X, D236A, but did co-
IP with FLAG-FAM83HS287X and FLAG-FAM83HWT (Fig. 6C). The co-
localisation of mCherry-CK1α and FLAG-FAM83HS287X was compared
with that of FLAG-FAM83HS287X, D236A. FLAG-FAM83HS287X had a
predominantly nuclear localisation with overlapping mCherry-CK1α
localisation (Fig. 6D). Interestingly, FLAG-FAM83HS287X, D236A could be
observed to have two different localisation patterns; some cells had a
Fig. 3. The interaction between FAM83H and CK1 is not mediated by the canonical F-x-x-x-F motif.
A Sequence alignment of Homo sapiens (human), Mus musculus (mouse), Xenopus tropicalis and Danio rerio FAM83H proteins. Shading indicates percentage sequence
identity as shown in key. F-x-x-x-F motifs are highlighted by a magenta box. Generated using ClustalO [58] in Jalview [59].
B U2OS FAM83H-/- cells transiently expressing FLAG empty (vector), FLAG-FAM83HD236A, FLAG-FAM83HF247A, FLAG-FAM83HF251A, FLAG-FAM83HF270A, FLAG-
FAM83HF274A, FLAG-FAM83HF278A, FLAG-FAM83HF350A, FLAG-FAM83HF354A and FLAG-FAM83HWT were lysed and FLAG was immunoprecipitated from cell lysates
using anti-FLAG antibodies conjugated to agarose gel. Input and IP samples were resolved by SDS-PAGE and immunoblotted (IB) with the antibodies shown. n = 2.
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Fig. 4. The interaction between FAM83H and NCK is mediated by the second and third SH3 domains of NCK.
A Schematic representation of dominant negative NCK mutants generated for use in C. Mutated domains are indicated by crosses and are greyed out. The mutated
residues are shown above the domain. W is tryptophan, K is lysine, R is arginine, and M is methionine.
B As A but for NCK2 and for use in D.
C A single copy of GFP-FAM83H was introduced stably downstream of a doxycycline inducible promoter in U2OS Flp-In T-REx cells. Cells were transiently trans-
fected with FLAG empty vector (vector) FLAG-NCK2R308M(SH2*), FLAG-NCK2W39K (SH3–1*), FLAG-NCK2W143K (SH3–2*), FLAG-NCK2W229K (SH3–3*), FLAG-
NCK2W39K, W144K (SH3–1/2)*, FLAG-NCK2W39K, W229K (SH3–1/3*), FLAG-NCK2W143K, W229K (SH3–2/3*), or FLAG-NCK2W39K, W143K, W229K (SH3–1/2/3*). Cell ex-
tracts (input) and anti-FLAG immunoprecipitates (IP) were resolved by SDS-PAGE then immunoblotted. n = 1.
D As C, but the following constructs were used instead FLAG empty vector (vector), FLAG-NCK2R311M(SH2*), FLAG-NCK2W39K (SH3–1*), FLAG-NCK2W149K
(SH3–2*), FLAG-NCK2W235K (SH3–3*), FLAG-NCK2W39K, W149K (SH3–1/2)*, FLAG-NCK2W39K, W235K (SH3–1/3*), FLAG-NCK2W149K, W235K (SH3–2/3*), or FLAG-
NCK2W39K, W149K, W235K (SH3–1/2/3*). n = 2.
E Fragments of FAM83H for F were generated as shown. Numbers indicate the residues of FAM83H. Blue boxes indicate proline rich motifs.
F U2OS FAM83H-/- cells were transiently transfected with FLAG empty vector (vector), or fragments from C tagged with an N-terminal FLAG tag and wild type
FAM83H (WT) or not transfected at all (−). Cells were lysed then subjected to anti-FLAG immunoprecipitation. Cell extracts (input) and immunoprecipitates (IP)
were resolved by SDS-PAGE and immunoblotted. Exp.: exposure. n = 2.
G Schematic diagram representing the interaction sites between FAM83H and CK1 and NCK identified by our lab.
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purely diffused cytoplasmic localisation, whereas some cells had both
nuclear and cytosolic diffused localisation (Fig. 6D). This implies that
while the interaction between FAM83H and CK1 may have some impact
on the nuclear localisation of FAM83H, another protein or multiple
proteins may have an influence on the nuclear localisation of FAM83H.
3.6. Characterisation of FAM83H interaction with CK1 and NCK at the
endogenous level
Thus far, we have primarily employed overexpression systems to
investigate FAM83H interactors. Therefore, we sought to validate these
interactions at the endogenous level. To do this, we used CRISPR/Cas9
genome editing technology to knockin a gene that encodes enhanced
fluorescent GFP (EGFP) into the native FAM83H gene locus of A549
lung adenocarcinoma cells to encode FAM83H protein with an en-
dogenous C-terminal GFP tag (Fig. 7A). A single cell clone with
homozygous C-terminal GFP tag insertion on FAM83H was validated by
Western blotting with the disappearance of the endogenous FAM83H
signal and concurrent reappearance of a band at a higher molecular
weight equivalent to the added GFP (Fig. 7B). Anti-GFP IPs from these
cells, but not from WT cells overexpressing GFP control, pulled down
FAM83H as well as CK1α, δ and ε (Fig. 7B). Analysis of the anti-GFP IPs
by mass fingerprinting also identified FAM83H, CK1α, CK1δ and CK1ε
in samples from A549 FAM83HGFP/GFP cells (Fig. 7C). However, under
these conditions, NCK proteins could not be detected in anti-GFP IPs,
either by Western blotting or mass fingerprinting (Fig. 5B, C). This
suggests the interaction between FAM83H and NCK is potentially
transient in nature, or requires a stimulus.
In a similar manner to the generation of A549 FAM83HGFP/GFP cells,
an endogenous mCherry tag was knocked into the endogenous
CSNK1A1, CSNK1D and CSNK1E gene loci of U2OS cells, which encode
CK1α, CK1δ and CK1ε proteins respectively. As such, these cells ex-
pressed mCherry-tagged CK1 isoforms (Fig. 7D). mCherry was im-
munoprecipitated from cell lysates and lysates from U2OS wild type
cells were used as a control. IPs were analysed by mass spectrometry. As
expected [5], PAWS1 was uniquely identified in mCherry-CK1α IPs by
mass spectrometry, but not in mCherry-CK1δ, mCherry-CK1ε nor con-
trol IPs (Fig. 7E). FAM83H was identified in mCherry-CK1α, mCherry-
CK1δ and mCherry-CK1ε IPs but not control IPs by mass spectrometry
(Fig. 7E) and this was validated by Western blotting (Fig. 7F).
3.7. Proximity based labelling to investigate the protein components of
FAM83H speckles
We uncovered that FAM83H disease mutants may cause the mis-
localisation of CK1, but do not affect its kinase activity. Moreover, the
nuclear localisation of disease mutants is not solely mediated by in-
teraction with CK1. Nevertheless, wildtype FAM83H and disease mu-
tants localise in speckles, while none of the other 7 FAM83 proteins
localise to speckles of a similar nature [1,2]. The interaction of
FAM83H with CK1 isoforms and NCK does not fully explain the de-
terminants of the speckles. Thus, identifying the key components of
these speckles might reveal functional insights into FAM83H. As these
speckles appear as compact, condensed structures, we sought to identify
the protein components of these speckles by utilising enzymatic
proximity-based labelling approaches founded on the high affinity non-
covalent interaction between biotin and streptavidin. We utilised Tur-
boID, a mutant derivative of BioID with a substantial improvement in
biotinylation kinetics from hours to minutes [35]. TurboID is able to
biotinylate proximal proteins upon incubation of cells with biotin for
just 10 min [35]. We fused TurboID to an anti-GFP nanobody that
contains 6 destabilising mutations (aGFP6M) [45], which lead to the
degradation of the fusion protein in the absence of GFP (Fig. 8A),
thereby reducing the amount of free TurboID-aGFP6M. We infected
stable U2OS cells that express FAM83H-GFP or FAM83E-GFP upon
doxycycline stimulation with retroviruses encoding either FLAG-Tur-
boID-aGFP6M or FLAG-TurboID control. Upon incubation of these cells
with biotin, TurboID would be expected to biotinylate proteins prox-
imal to FAM83H-GFP (speckled localisation) and FAM83E-GFP (non-
speckled localisation) (Fig. 8B). First, we sought to optimise the con-
centration of biotin for optimal biotinylation. Western blotting of cell
extracts indicated that maximal amount of biotinylated material was
detected following incubation of just 50 μM biotin (Fig. 8C), and
therefore, for further experiments, cells were incubated in 50 μM biotin.
FLAG-TurboID-aGFP6M or FLAG-TurboID alone control retrovirus
transduced cells expressing FAM83H-GFP or FAM83E-GFP were then
incubated with 50 μM biotin for 10 min, biotinylation immediately
quenched and cells stained with Streptavidin conjugated to Alexa Fluor-
594, to recognise biotinylated proteins, and visualised. Proteins bioti-
nylated by TurboID-aGFP6M could be seen to robustly colocalise with
FAM83H-GFP or FAM83E-GFP, however proteins biotinylated by FLAG-
TurboID alone did not (Fig. 8D). Moreover, when biotinylated proteins
were subjected to streptavidin pull-down, FAM83H-GFP and FAM83E-
GFP could be robustly detected from streptavidin pull downs and CK1α
and CK1ε could also be detected (Fig. 8E).
3.8. Iporin and BAG3 may be protein components of FAM83H speckles
As TurboID was able to robustly biotinylate known interactors CK1α
and CK1ε, this suggested TurboID could be utilised to characterise the
components of the FAM83H speckles by TurboID-mediated biotinyla-
tion followed by mass spectrometry analysis of the biotinylated pro-
teome. U2OS cells expressing FAM83H-GFP or FAM83E-GFP and FLAG-
TurboID or FLAG-TurboID-aGFP6M were incubated with 50 μM biotin
for 10 min. Streptavidin pull-downs were employed to enrich biotiny-
lated proteins from extracts. Pull-downs were resolved by SDS-PAGE
(Fig. 9A) then the proteins were identified by mass spectrometry
(Fig. 9A-D). FAM83H was enriched in cells expressing FAM83H-GFP
and TurboID-aGFP6M relative to TurboID control. A similar result was
seen from cells expressing FAM83E-GFP, where FAM83E enrichment
was seen with TurboID-aGFP6M. As expected, CK1α, CK1δ and CK1ε
were observed as proximal proteins of both FAM83E and FAM83H
(Fig. 9B). Moreover, CEP170, VPS13B, AKAP9 and CEP131, which our
previous mass spectrometry data indicates are interactors of FAM83E
[1], were also identified as proximal proteins to FAM83E but not
FAM83H (Fig. 9B, D). Out of the hundreds of FAM83H proximal pro-
teins identified, two proteins stood out as interesting hits. These include
the BAG family molecular chaperone regulator 3 (BAG3) and
Fig. 5. Wild type FAM83H and disease mutants co-localise with CK1, but mutants do not colocalise with NCK1.
A U2OS FAM83H-/- cells transiently expressing GFP, GFP-FAM83H, mCherry-NCK1 or mCherry-NCK2, as indicated, were fixed and stained with 4′,6-diamidino-2-
phenylindole (DAPI). Cells were imaged using the DeltaVision widefield fluorescence microscope then images were deconvolved and processed using OMERO (12).
Scale bar represents 10 μm. n = 3
B As A but U2OS FAM83H-/- cells were transiently transfected with FLAG-FAM83HWT (WT), FLAG-FAM83HS287X (S287X), FLAG-FAM83HQ452X (Q452X), FLAG-
FAM83HE694X (E694X), or no FLAG construct (−) and co-transfected with mCherry-CK1α. Scale bar represents 10 μm. n = 3
C As B but with mCherry-NCK1 instead of mCherry-CK1α. n = 2
D U2OS FAM83H-/- cells transiently expressing FLAG (vector), FLAG-FAM83HS342T, FLAG-FAM83HG557C, FLAG-FAM83HWT and mCherry-CK1α were fixed and
stained with anti-FLAG antibodies and DNA stained with DAPI. Cells were imaged using DeltaVision widefield fluorescence microscope. Scale bar represents 10 μm.
n = 2
E As D but mCherry-NCK1 was used instead of mCherry-CK1α. Scale bar represents 10 μm. n = 1
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Fig. 6. CK1 associated with FAM83HQ452X maintains kinase activity.
A FLAG empty vector (vector), FLAG-FAM83HQ452X, FLAG-FAM83HD236A and FLAG-FAM83HWT were transiently transfected into U2OS FAM83H-/- cells. Cells were
then lysed and lysates subjected to anti-FLAG immunoprecipitation. Cell extract (input) and immunoprecipitates (IP) were resolved by SDS-PAGE then im-
munoblotted (IB) with the antibodies indicated. n = 2.
B As A but immunoprecipitates were incubated with recombinant GST (glutathione S-transferase)-PAWS1-His in the presence of [γ32P]-ATP (adenosine 5′-tripho-
sphate). Once the reaction was quenched, samples were resolved by SDS-PAGE. The gel was stained with InstantBlue (top) then dried and subjected to 32P radio-
graphy (bottom). n = 2.
C U2OS FAM83H-/- cells were transiently transfected with FLAG empty vector (vector), FLAG-FAM83HD236A, FLAG-FAM83HS287X, FLAG-FAM83HS287X, D236A and
FLAG-FAM83HWT. Cells were lysed and lysates incubated with anti-FLAG beads for 16 h. Immunoprecipitates (IP) and cell extracts (input) were resolved by SDS-
PAGE and proteins immunoblotted with the antibodies indicated. n = 2.
D U2OS FAM83H-/- cells transiently expressing FLAG-FAM83HS287X, FLAG-FAM83HS287X, D236A, FLAG-FAM83HWT and mCherry-CK1α were stained with anti-FLAG
and DNA stained with DAPI. n = 2
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Fig. 7. The interaction between FAM83H and CK1 can be detected at an endogenous level.
A Schematic diagram to represent the mechanism by which A549 FAM83HGFP/GFP cells were generated using CRISPR/Cas9 genome editing technology. Arrows (^)
represent guide RNAs. HA – homology arm.
B GFP was immunoprecipitated from lysates of A549 FAM83HWT/WT transiently expressing GFP (WT + GFP) and A549 FAM83HGFP/GFP (KI) cells. Whole cell lysates
(input) and immunoprecipitated proteins (IP) were resolved by SDS-PAGE then analysed by immunoblotting with the antibodies shown. n = 1.
C As B, but after resolving samples by SDS-PAGE, the gel was stained in InstantBlue, the gel pieces were excised then processed and proteins digested with trypsin and
peptides analysed by mass spectrometry. The table shows total spectral counts of FAM83H, CK1α, CK1δ and CK1ε. n = 1.
D Schematic representation of mCherry-CK1 knockin proteins.
E U2OS CK1mCherry/mCherry cells or control U2OS wild type cells (−) were lysed, resolved by SDS-PAGE, stained in InstantBlue then gel pieces excised then processed
and proteins digested with trypsin. Peptides were then analysed by mass spectrometry and total spectral counts are shown in the table. n = 1.
F Cells from E were lysed and mCherry immunoprecipitated from cell lysates. Immunoblot shows cell extracts (input), immunoprecipitate (IP) and flow through (FT)
samples. n = 2.
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Fig. 8. Proximity based labelling to investigate the protein components of FAM83H speckles.
A U2OS wild type cells were transduced with retroviruses encoding FLAG-aGFP6M. These cells were then transfected with a vector encoding GFP or not transfected.
Lysates were resolved by SDS-PAGE on a 13% protein gel then immunoblotted (IB) as indicated. n = 1.
B Schematic representation of TurboID-aGFP6M and its mechanism of action.
C U2OS Flp-In T-REx cells that express FAM83H-GFP under a doxycycline-inducible promoter were infected with retroviruses encoding FLAG-TurboID or FLAG-
TurboID-aGFP6M. These stable cell lines were induced for 24 h then incubated with the indicated concentrations of biotin for 10 min. After incubation, cells were
lysed, resolved by SDS-PAGE and immunoblotted (IB) as indicated. n = 1.
D Cells from C were incubated with 50 μM biotin for 10 min, then fixed and stained with streptavidin conjugated to Alexa Fluor 594. DNA was stained with DAPI.
Scale bar represents 10 μm. n = 1
E U2OS Flp-In T-REx cells expressing FLAG-TurboID or FLAG-TurboID-aGFP6M and expressing either FAM83H-GFP or FAM83E-GFP were incubated with 50 μM
biotin for 10 min then lysed and subjected to streptavidin pull down and whole cell lysates (input) and pull downs were immunoblotted (IB) with the antibodies
indicated. n = 1.
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Interacting protein of rab1 (Iporin) (Fig. 9B-D). Subsequent character-
isation of these proteins as potential constituents of the FAM83H-lo-
calised speckles needs to be performed.
4. Discussion
The cellular and biochemical roles of FAM83H remain poorly
characterised. The identification of over 20 unique autosomal dominant
FAM83H mutations in patients with hypocalcified amelogenesis im-
perfecta makes it pertinent to understand its function. The FAM83
protein family direct protein kinase CK1 isoforms to distinct subcellular
compartments, and FAM83H directs CK1α, δ and ε isoforms to cyto-
plasmic and nuclear speckle-like structures [1,2]. Here, we show the
pathogenic mutants of FAM83H retain association with CK1 isoforms,
do not influence the associated CK1 catalytic activity, however localise,
and in the process direct CK1 isoforms, to the nucleus. We also report
(caption on next page)
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the identification of NCK1/2 as novel interactors of FAM83H in extracts
and cells. The SH3–2 and SH3–3 domains of NCKs mediate the inter-
action with the C-terminal proline-rich domain of FAM83H and there-
fore this interaction is lost with FAM83H AI truncation mutants. We
propose that FAM83H truncation mutants potentially leads to AI pa-
thogenicity through either mis-directed CK1 activity in the nucleus, the
loss of FAM83H-NCK association or a combination of both.
We identified a 50 amino acid residue sequence containing two
separate proline rich sequences P915-V916-P917-P918−V919-P920 and P926-
V927-P928-P929-V930-P931 that, we believe, mediates the interaction be-
tween FAM83H and NCK. The proline rich sequences are flanked by
positively charged arginine residues N-terminal and C-terminal
to the proline rich PVPPVP motifs i.e. E910RRGSP915VPPVP
E921RRSSP926VPPVPE932RRGS. These interaction sites conform to the
canonical class I (+xxPxxP) and class II (xPxxPx+) ligands for SH3
binding [46], where + indicates a positively charged residue, which
strengthens the interaction with SH3 domains. These two ligands are
known to bind SH3 domains in opposite orientations, therefore one may
infer that interaction between FAM83H and NCK can occur in two
different orientations. Interestingly, DOCK180, like FAM83H, was ob-
served to interact with the SH3–2 and SH3–3 domains of NCK2, where
SH3–3 seemed to be the major interaction site [47]. Moreover, NCK
may interact with multiple proline rich sequences on DOCK180 [47].
Here, interaction of DOCK180 with two SH3 domains of NCK2, enables
NCK2 to have a higher affinity interaction with DOCK180 [47]. Two
other proline rich motifs exist outside the identified 50 amino acid
stretch, however these motifs and their surrounding residues and
charges are vastly different to the aforementioned motifs, and this could
therefore explain why these other motifs did not interact with NCK1.
We could not robustly detect interaction between FAM83H and NCK at
an endogenous level when we performed anti-GFP IPs utilising our
A549 FAM83HGFP/GFP cell line. Although IPs in which we were able to
detect interaction between FAM83H and NCK were performed using
U2OS and HEK-293 cell lysates, these were under conditions where
FAM83H was overexpressed. Moreover, our original proteomics data
where FAM83H was overexpressed indicates that the spectral counts of
NCK1 and NCK2 in anti-GFP-FAM83H IPs were much lower when
compared to CK1 isoforms. As NCK is involved in tyrosine kinase sig-
naling [48], one could speculate that a stimulus may be involved in
mediating endogenous interaction between the two proteins. Our initial
attempts at identifying a stimulus that induces FAM83H-NCK interac-
tion have been unsuccessful and therefore further investigation into a
stimulus, or stimuli, which regulate(s) this interaction at an endogenous
level is needed. This may provide key functional insights into how
FAM83H mediates intracellular signaling in response to extracellular
signals.
The peculiar speckle-like localisation of FAM83H and the truncated
mutants, albeit in different subcellular compartments, suggests that
understanding the nature and constituents of these speckles could help
unravel cellular roles of FAM83H. In our attempts to identify the
components of FAM83H speckles, using a modified TurboID proximity
labelling we identified some novel proteins, including Iporin and BAG3,
as potential constituents of FAM83H-associated speckles. Iporin (in-
teracting protein of Rab1), also known as RUSC2 (RUN and SH3 do-
main-containing protein 2), is a 161 kDa protein primarily known for its
functions in binding Rab1 GTPase [49]. Iporin comprises a single SH3
domain, one RUN domain, two polyproline stretches and one poly-
glutamic acid stretch. While the function of RUN domains is mostly
uncharacterised, RUN domains are believed to have some importance in
Rab protein functions. The RUN domain is responsible for the interac-
tion between Iporin and Rab1 and Rab35 GTPases [49,50], where this
interaction between Rab1 and Iporin is believed to have some im-
portance in the transport of vesicles [49]. Moreover, Iporin (RUSC2),
and RUSC1 (also known as NESCA), are thought to be Adapter Protein
complex 4 (AP-4) accessory proteins [51]. AP-4 is an AP complex in-
volved in packaging proteins into vesicles and having roles in the
transport and budding of these vesicles. AP-4 packages Autophagy re-
lated gene 9A protein (ATG9A) into vesicles, in an Iporin dependent
manner and these AP-4 derived vesicles were seen to localise proximal
to autophagosomes in cells that were starved of serum [51,52]. Inter-
estingly, BAG3 also has links to the formation of autophagosomes and
linking polyubiquitinated protein clients targeted for proteasomal de-
gradation to autophagy [53–55]. BAG3 also links with dynein micro-
tubule motor proteins and 14–3-3 proteins to transport clients to ag-
gresomes [54–56], which are compartments found proximal to the
nucleus in which much autophagy occurs [57]. BAG3 is a stress-induced
protein which functions as a co-chaperone, interacting with 70 kDa
heat shock protein (HSP70) to encourage the release of HSP70 protein
clients.
The next steps are to investigate the putative subcellular co-locali-
sation and interactions between FAM83H and Iporin and BAG3 and
determine potential biological significance of these interactions. It
would also be interesting to investigate whether these two proteins lose
interaction with mutants of FAM83H that do not interact with CK1, as
the interaction between FAM83H and CK1 is necessary for the speckle-
like localisation pattern of FAM83H [9].
Amelogenesis is a complex process, in which the role played by
FAM83H is not completely clear. However, we are optimistic that our
characterisation of the molecular roles and interactors of FAM83H, will
prove to be useful for those conducting research into amelogenesis and
will help shed a new light onto novel proteins that may play a role in
amelogenesis.
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Fig. 9. Iporin and BAG3 may be protein components of FAM83H speckles.
A U2OS Flp-In T-REx cells induced to express FAM83H-GFP or FAM83E-GFP and expressing FLAG-TurboID or FLAG-TurboID-aGFP6M were incubated with 50 μM
biotin for 10 min. Cells were then lysed, lysates subjected to Streptavidin pull downs then resolved by SDS-PAGE. Gel pieces were excised as indicated by dotted lines.
n = 1.
B, C, D As A but after excision, gel pieces were processed then digested with trypsin. Samples were analysed using LC-MS/MS and Scaffold version 4.8.6. n = 1.
B Table showing the total spectral counts of some hits identified via mass spectrometry. n = 1 Proteins in pink indicate known interactors of FAM83H, green
indicates novel proximal proteins of FAM83H identified in this paper, blue indicates known interactors of FAM83E.
C, D Total spectral counts of proteins are plotted where magenta circles indicate a known interactor of FAM83H, green circles indicate a novel hit and blue circles
indicate known interactors of FAM83E. n = 1
C Scatter plot shows spectral counts from samples in which cells were expressing FAM83H-GFP and FLAG-TurboID or FLAG-TurboID-aGFP6M. Left plot shows all
proteins identified. Right plot is missing 18 identified proteins and has a smaller scale to enable better visualisation of the identified proteins. n = 1.
D Scatter plot shows spectral counts from samples in which cells were expressing FAM83H-GFP or FAM83E-GFP and FLAG-TurboID-aGFP6M. Left plot shows all the
proteins that were identified. Right plot is missing 18 identified proteins and has a smaller scale to enable better visualisation of the identified proteins. n = 1.
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